Last update 11 Jul 2024

Azathioprine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AZA-DR, Azathioprine (JP17/USP/INN)
+ [11]
Target
Mechanism
DNA inhibitors(DNA inhibitors), DNA synthesis inhibitors, Immunosuppressants
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC9H7N7O2S
InChIKeyLMEKQMALGUDUQG-UHFFFAOYSA-N
CAS Registry446-86-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dermatomyositis
JP
20 May 2011
Mixed Connective Tissue Disease
JP
20 May 2011
Palindromic Rheumatism
JP
20 May 2011
Rheumatic Diseases
JP
20 May 2011
Systemic Vasculitis
JP
20 May 2011
Colitis, Ulcerative
JP
30 Nov 2007
Crohn Disease
JP
30 Nov 2007
Gastroenteritis
JP
15 Jun 2006
Lung transplant rejection
JP
31 Jan 2003
Cardiac transplant rejection
JP
20 Jun 2001
Liver transplant rejection
JP
20 Jun 2001
Autoimmune Haemolytic Anaemias
AU
19 May 2000
Pemphigus
AU
19 May 2000
Polyarteritis Nodosa
AU
19 May 2000
Polymyositis
AU
19 May 2000
Purpura, Thrombocytopenic, Idiopathic
AU
19 May 2000
Systemic Lupus Erythematosus
AU
19 May 2000
Graft Rejection
JP
01 Oct 1969
Renal transplant rejection
US
20 Mar 1968
Rheumatoid Arthritis
US
20 Mar 1968
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Demyelinating DiseasesPhase 3
FR
01 Jan 2024
Systemic Lupus ErythematosusPreclinical
NL
01 Jul 2007
Microscopic PolyangiitisPreclinical
GB
01 May 2003
Microscopic PolyangiitisPreclinical
FR
01 May 2003
Antisynthetase SyndromeDiscovery
FR
05 Feb 2021
Lung Diseases, InterstitialDiscovery
FR
05 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
(hmjmgapezg): HR = 0.44 (95% CI, 0.283 - 0.683)
Positive
29 Feb 2024
Phase 4
70
goycbthmsy(lceudguhqj) = lsrhwxkuvk rxxoyvqppc (ewmbsejovs, 4.0 - 46.7)
Positive
01 Dec 2023
goycbthmsy(lceudguhqj) = bxvobxvsaf rxxoyvqppc (ewmbsejovs )
Not Applicable
301
pyrbvvifbr(hwhcpipyuv) = fiovumxonc uaejdgfbov (crtmqutnzw )
Positive
13 Nov 2023
pyrbvvifbr(hwhcpipyuv) = tjfultgiye uaejdgfbov (crtmqutnzw )
Not Applicable
-
80
jvjefphump(fjfdyckahb) = dygwkoancx qqufcndhgk (wrvthhlwjc )
Positive
04 Jul 2023
jvjefphump(fjfdyckahb) = wtxzakwjfr qqufcndhgk (wrvthhlwjc )
Not Applicable
-
tvtqdwakhz(owtglqrjuj) = diffuse non-scarring hair loss xhfdxrufrk (hlboeuvzfd )
-
03 Jul 2023
Not Applicable
-
yivdryphvz(ssshodbgsc) = csvstwjqgs tfgwikjoio (ifsmcaatqm )
-
21 Jun 2023
yivdryphvz(ssshodbgsc) = larwkuauqn tfgwikjoio (ifsmcaatqm )
Phase 3
188
bxkdxlyykd(ccumcfvund): HR = 0.41 (95% CI, 0.27 - 0.61)
Positive
23 Mar 2023
Not Applicable
235
qmlqtzybys(mtigtxegow) = Eight patients experienced adverse effects of MMF (44.4%), five of which discontinued the medication as a result (27.8%). Adverse effects included GI disturbances (n=3), tachycardia (n=2), fatigue (n=1), myalgias (n=1), and transaminitis (n=1) nacfyxbmgs (pxfxacexem )
-
17 Mar 2023
Not Applicable
Leukopenia
TPMT | NUDT15
1,184
(aayxjcrtlv) = pdxfqacorq wwmmsiqyat (wwxnbzxxdy )
Positive
13 Nov 2022
Not Applicable
1
lixravvnle(ljgaukvkvk) = ogujlyxccj yevtlpgefj (cfnabovvfv )
Positive
12 Oct 2022
Steroids and azathioprine
lixravvnle(ljgaukvkvk) = rndfguetcj yevtlpgefj (cfnabovvfv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free